Education
About Us
Working with TipRanks
Follow Us
CSL Limited (CMXHF)
:CMXHF
CMXHF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$137.40 - $215.00
Previous CloseN/A
Volume29.00
Average Volume (3M)1.21K
Market Cap
$75.07B
Enterprise Value$156.94B
Total Cash (Recent Filing)$728.82M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)26.4
Beta0.40
Next Earnings
Aug 19, 2025EPS Estimate
2.27Last Dividend Ex-Date
Mar 10, 2025Dividend Yield1.87%
Share Statistics
EPS (TTM)5.68
Shares Outstanding484,212,130
10 Day Avg. Volume1,514
30 Day Avg. Volume1,214
Financial Highlights & Ratios
PEG Ratio2.78
Price to Book (P/B)N/A
Price to Sales (P/S)8.50
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap2.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit20.76
Enterprise Value/Ebitda16.46
Forecast
1Y Price Target
$201.80Price Target Upside36.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
---
CSL News
PremiumCompany Announcements
CSL Limited Announces Cessation of Securities
PremiumCompany Announcements
CSL Monitors U.S. Tariff Developments to Safeguard Medicine Access
PremiumCompany Announcements
CSL Limited Announces Director’s Share Acquisition
PremiumCompany Announcements
CSL Limited Announces Cessation of Securities
PremiumCompany Announcements
CSL Limited Updates Dividend Distribution Details
PremiumCompany Announcements
CSL Limited Issues Unquoted Equity Securities Under Employee Incentive Scheme
PremiumCompany Announcements
CSL Limited Announces Quotation of New Securities on ASX---
Options Prices
Currently, No data available
---
Ownership Overview
0.05% Insiders
5.04% Mutual Funds
<0.01% Other Institutional Investors
86.92% Public Companies and
Individual Investors
CMXHF FAQ
What was CSL Limited’s price range in the past 12 months?
CSL Limited lowest stock price was $137.40 and its highest was $215.00 in the past 12 months.
What is CSL Limited’s market cap?
CSL Limited’s market cap is $75.07B.
When is CSL Limited’s upcoming earnings report date?
CSL Limited’s upcoming earnings report date is Aug 19, 2025 which is in 113 days.
How were CSL Limited’s earnings last quarter?
CSL Limited released its earnings results on Feb 11, 2025. The company reported $4.29 earnings per share for the quarter, missing the consensus estimate of $4.414 by -$0.124.
Is CSL Limited overvalued?
According to Wall Street analysts CSL Limited’s price is currently Undervalued.
Does CSL Limited pay dividends?
CSL Limited pays a Annually dividend of $1.323 which represents an annual dividend yield of 1.87%. See more information on CSL Limited dividends here
What is CSL Limited’s EPS estimate?
CSL Limited’s EPS estimate is 2.27.
How many shares outstanding does CSL Limited have?
CSL Limited has 484,212,130 shares outstanding.
What happened to CSL Limited’s price movement after its last earnings report?
CSL Limited reported an EPS of $4.29 in its last earnings report, missing expectations of $4.414. Following the earnings report the stock price went down -3.512%.
Which hedge fund is a major shareholder of CSL Limited?
Currently, no hedge funds are holding shares in CMXHF
---
CSL Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$201.80 (36.20% Upside)
$201.80 (36.20% Upside)
Blogger Sentiment
Bullish
CMXHF Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $32.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.92%
12-Months-Change
Fundamentals
Return on Equity
15.38%
Trailing 12-Months
Asset Growth
3.06%
Trailing 12-Months
Company Description
CSL Limited
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
---
CMXHF Company Deck
---
CMXHF Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive sentiment, with strong financial performance led by CSL Behring and a promising outlook despite challenges in CSL Seqirus and specialty products due to external market conditions.Read More>---
CMXHF Stock 12 Month Forecast
Average Price Target
$201.80
▲(36.20% Upside)
Technical Analysis
Ansell
―
Cochlear Limited
―
Ramsay Health Care
―
Sonic Healthcare Limited
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―
Best Analysts Covering CMXHF
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-4.01%
reiterated a buy rating 13 days ago
Copying David Bailey's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -4.01% per trade.
---